Plain-English summary
Does promoting a carved-out generic version amount to inducing patent infringement?
This case asks whether statements like calling a product a “generic version” or citing public information about the brand are enough to allege that a generic maker induced infringement of a patented, carved-out use. The Court will decide what facts a plaintiff must plausibly plead to state a claim for induced infringement when the generic label omits the patented use.
Why this matters
The decision will affect how easily branded drug makers can sue generic competitors for induced infringement when generics avoid the patented use on their labels. It will shape what evidence plaintiffs must plead early on, influence litigation costs, and affect how generics describe and market carved-out products — with consequences for competition, drug prices, and innovation incentives.
Who may feel it
- Branded pharmaceutical companies holding method-of-use patents
- Generic drug manufacturers
- Pharmacies and physicians who prescribe or dispense generics
- Patients relying on generic medications
- Patent lawyers and the pharmaceutical industry generally
Key questions
- When a generic drug label fully carves out a patented use, are allegations that the generic maker calls its product a "generic version" and cites public information about the brand enough to plausibly allege induced infringement?